Source comparison
Peptides for TBI Recovery: Mechanism Comparison
Cerebrolysin Neurotrophic signaling (BDNF/NGF-like activity) TrkB, TrkA Intravenous infusion Phase III completed for stroke; Phase II for TBI Strongest clinical evidence for functional recovery in moderate-to-severe TBI when initiated within 72 hours P21 Micro
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Neurotrophic signaling (BDNF/NGF-like activity)
- TrkB, TrkA
- Intravenous infusion
- Phase III completed for stroke; Phase II for TBI
- Strongest clinical evidence for functional recovery in moderate-to-severe TBI when initiated within 72 hours
- P21
- Microtubule stabilization, tau regulation
- Microtubule-associated proteins
- Intranasal, subcutaneous
- Preclinical only
- Promising for preventing chronic neurodegeneration (CTE risk) but human data lacking
- Dihexa
- HGF/c-Met pathway activation, synaptogenesis
- c-Met receptor
- Oral
- High bioavailability and cognitive enhancement in animal models; human trials needed
- Thymalin
- Immune modulation, neuroinflammation reduction
- Thymus peptide receptors
- Subcutaneous
- Preclinical + observational studies
- Potential adjunct for reducing secondary inflammatory injury